Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

Introduction: The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 recognized substantial progress in the pathological characterization of breast cancer subtypes. A useful surrogate definition was developed to distinguish luminal A-like breast cancer from luminal B-like disease based on a combination of estrogen receptor (ER), progesterone receptor (PgR) and Ki-67 status, without a requirement for molecular diagnostics. Differences depend upon the choice of the threshold value for Ki-67 and the requirement for substantial PgR positivity. We aimed to verify the suitability of the new surrogate definitions of luminal subtypes in terms of distant disease control in a large series of patients.Methods: We studied 9,415 women with a median follow-up of 8.1 years who (1) had ER-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer and (2) had undergone surgery at the European Institute of Oncology between 1994 and 2006. We evaluated distant disease-free survival of patients with " low" (

Original languageEnglish
Article numberR65
JournalBreast Cancer Research
Volume16
Issue number3
DOIs
Publication statusPublished - Jun 20 2014

Fingerprint

Breast Neoplasms
Progesterone Receptors
Estrogen Receptors
Molecular Pathology
Disease-Free Survival
human ERBB2 protein
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

@article{ecc964c15e4b42279d854bf8279535dd,
title = "Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes",
abstract = "Introduction: The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 recognized substantial progress in the pathological characterization of breast cancer subtypes. A useful surrogate definition was developed to distinguish luminal A-like breast cancer from luminal B-like disease based on a combination of estrogen receptor (ER), progesterone receptor (PgR) and Ki-67 status, without a requirement for molecular diagnostics. Differences depend upon the choice of the threshold value for Ki-67 and the requirement for substantial PgR positivity. We aimed to verify the suitability of the new surrogate definitions of luminal subtypes in terms of distant disease control in a large series of patients.Methods: We studied 9,415 women with a median follow-up of 8.1 years who (1) had ER-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer and (2) had undergone surgery at the European Institute of Oncology between 1994 and 2006. We evaluated distant disease-free survival of patients with {"} low{"} (",
author = "Patrick Maisonneuve and Davide Disalvatore and Nicole Rotmensz and Giuseppe Curigliano and Marco Colleoni and Silvia Dellapasqua and Giancarlo Pruneri and Mastropasqua, {Mauro G.} and Alberto Luini and Fabio Bassi and Gianmatteo Pagani and Giuseppe Viale and Aron Goldhirsch",
year = "2014",
month = "6",
day = "20",
doi = "10.1186/bcr3679",
language = "English",
volume = "16",
journal = "Breast Cancer Research",
issn = "1465-5411",
publisher = "BioMed Central",
number = "3",

}

TY - JOUR

T1 - Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes

AU - Maisonneuve, Patrick

AU - Disalvatore, Davide

AU - Rotmensz, Nicole

AU - Curigliano, Giuseppe

AU - Colleoni, Marco

AU - Dellapasqua, Silvia

AU - Pruneri, Giancarlo

AU - Mastropasqua, Mauro G.

AU - Luini, Alberto

AU - Bassi, Fabio

AU - Pagani, Gianmatteo

AU - Viale, Giuseppe

AU - Goldhirsch, Aron

PY - 2014/6/20

Y1 - 2014/6/20

N2 - Introduction: The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 recognized substantial progress in the pathological characterization of breast cancer subtypes. A useful surrogate definition was developed to distinguish luminal A-like breast cancer from luminal B-like disease based on a combination of estrogen receptor (ER), progesterone receptor (PgR) and Ki-67 status, without a requirement for molecular diagnostics. Differences depend upon the choice of the threshold value for Ki-67 and the requirement for substantial PgR positivity. We aimed to verify the suitability of the new surrogate definitions of luminal subtypes in terms of distant disease control in a large series of patients.Methods: We studied 9,415 women with a median follow-up of 8.1 years who (1) had ER-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer and (2) had undergone surgery at the European Institute of Oncology between 1994 and 2006. We evaluated distant disease-free survival of patients with " low" (

AB - Introduction: The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 recognized substantial progress in the pathological characterization of breast cancer subtypes. A useful surrogate definition was developed to distinguish luminal A-like breast cancer from luminal B-like disease based on a combination of estrogen receptor (ER), progesterone receptor (PgR) and Ki-67 status, without a requirement for molecular diagnostics. Differences depend upon the choice of the threshold value for Ki-67 and the requirement for substantial PgR positivity. We aimed to verify the suitability of the new surrogate definitions of luminal subtypes in terms of distant disease control in a large series of patients.Methods: We studied 9,415 women with a median follow-up of 8.1 years who (1) had ER-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer and (2) had undergone surgery at the European Institute of Oncology between 1994 and 2006. We evaluated distant disease-free survival of patients with " low" (

UR - http://www.scopus.com/inward/record.url?scp=84904045535&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904045535&partnerID=8YFLogxK

U2 - 10.1186/bcr3679

DO - 10.1186/bcr3679

M3 - Article

VL - 16

JO - Breast Cancer Research

JF - Breast Cancer Research

SN - 1465-5411

IS - 3

M1 - R65

ER -